Postmenopausal Osteoporosis: How Treatment Changed Over Six Decades

Why Osteoporosis Is a Women's Disease First

Osteoporosis is not gender-neutral. Women account for approximately 80% of osteoporosis diagnoses in the United States, and the biology explains why. Estrogen actively suppresses osteoclast activity. When estrogen drops at menopause, osteoclasts run unchecked, dismantling trabecular bone faster than osteoblasts can replace it.

The numbers are stark. The Bone Health and Osteoporosis Foundation estimates that a 50-year-old white woman faces a lifetime hip fracture risk of roughly 17%, higher than her risk of breast and uterine cancer combined. A hip fracture in a woman over 65 carries a 20-30% mortality risk within the following year.

How Estrogen Loss Drives Bone Remodeling

During reproductive years, estrogen keeps the RANK/RANKL/OPG signaling axis in balance, limiting osteoclast lifespan. After the final menstrual period, circulating estradiol falls from roughly 100-400 pg/mL to below 20 pg/mL, lifting that brake. The result is a net bone-resorption excess that persists for years, not just the immediate postmenopausal window.

Perimenopause is the underappreciated turning point. Studies show bone loss accelerates 2-3 years before the final menstrual period, meaning a woman in her mid-40s with irregular cycles may already be losing bone at a measurable rate. This is one reason modern guidelines increasingly address perimenopausal bone health, not just postmenopausal.

The Pre-Treatment Era: What Happened Before 1960

Before effective pharmacotherapy existed, a woman with osteoporotic fractures received bed rest, a back brace, and sometimes traction. The condition did not even carry its modern name until 1941, when endocrinologist Fuller Albright linked postmenopausal bone loss to estrogen deficiency and coined the term "postmenopausal osteoporosis" in a landmark paper in JAMA.

Albright's insight was clinically ahead of its time. He proposed estrogen replacement as a logical intervention. Clinical medicine, however, moved slowly. Calcium and vitamin D supplementation became common practice in the 1950s, largely based on assumption rather than controlled trial data.

Fuller Albright's Contribution

Albright observed that postmenopausal women presenting with vertebral compression fractures had measurably lower urinary calcium balance than premenopausal women, and that estrogen administration partially corrected this. His framing of osteoporosis as an endocrine disease rather than an inevitable consequence of aging changed everything that followed, even if it took another three decades for randomized trial evidence to accumulate.

The Estrogen Decades: 1960s Through the 1990s

Estrogen became the dominant osteoporosis therapy for postmenopausal women across roughly four decades, a period shaped both by genuine clinical benefit and by an evolving understanding of risk.

Conjugated Equine Estrogen and the First Evidence Base

Conjugated equine estrogen (CEE, marketed as Premarin) received early FDA acknowledgment for menopausal symptoms in 1942. Through the 1970s, observational studies consistently showed that postmenopausal women taking estrogen had higher bone mineral density and lower fracture rates. The Lindsay et al. 1976 trial in Lancet provided the first randomized evidence that estrogen preserved bone density in early postmenopausal women, a result that cemented estrogen's role.

By the mid-1980s, the FDA formally approved estrogen for the prevention of postmenopausal osteoporosis. This was significant because it moved the indication from symptom relief to disease prevention, a different regulatory and clinical category.

The Endometrial Cancer Problem and the Progestogen Fix

The 1970s brought a serious safety signal. Women taking unopposed estrogen had a 4-8 times higher risk of endometrial cancer than untreated women. This was not a theoretical concern. Prescriptions for estrogen dropped sharply. The solution was the addition of a progestogen for women with an intact uterus, giving rise to combined hormone therapy (HT). Medroxyprogesterone acetate (MPA) became the most commonly added progestogen in the United States.

This combination is what the Women's Health Initiative (WHI) ultimately tested, with results that reshaped the field.

The WHI and the 2002 Inflection Point

The WHI was a randomized, placebo-controlled trial enrolling more than 16,608 postmenopausal women aged 50-79 across the CEE plus MPA arm. When the CEE/MPA arm was stopped early in 2002, the headlines focused on a statistically significant increase in breast cancer, coronary heart disease events, stroke, and pulmonary embolism. Hormone therapy prescriptions in the United States fell by more than 50% within two years.

What the headlines missed: the WHI also confirmed that CEE/MPA reduced hip fracture risk by 34% and total fractures by 24% compared with placebo. The bone benefit was real. The question was whether the overall risk-benefit balance justified use for osteoporosis as a primary indication, particularly in older women.

Subsequent WHI re-analyses, and the ongoing Nurses' Health Study, clarified the timing hypothesis: women who start HT close to menopause (within 10 years, or under age 60) show a very different cardiovascular risk profile than the older women who dominated the WHI cohort. The Menopause Society 2022 position statement now states that for healthy women under 60 or within 10 years of menopause onset, the benefits of HT generally outweigh the risks.

Bisphosphonates: The 1990s Revolution That Still Dominates

While the estrogen debate played out, a structurally different class of drugs was accumulating trial evidence. Bisphosphonates bind to hydroxyapatite in bone, are taken up by osteoclasts, and induce osteoclast apoptosis. They are anti-resorptive rather than bone-building.

Alendronate and the FIT Trial

Alendronate (Fosamax) received FDA approval for postmenopausal osteoporosis treatment in 1995. The key evidence came from the Fracture Intervention Trial (FIT), which showed alendronate reduced vertebral fracture risk by approximately 47% and hip fracture risk by 51% in women with existing vertebral fractures. FIT enrolled only postmenopausal women, making it one of the largest female-specific fracture trials of its era.

Alendronate's dosing flexibility (10 mg daily or 70 mg weekly) improved real-world adherence. It became the world's most prescribed osteoporosis medication through the late 1990s and 2000s.

Risedronate, Ibandronate, and Zoledronic Acid

Risedronate (Actonel) followed in 1998, with the VERT trial showing 41-49% reduction in new vertebral fractures over 3 years. Ibandronate added a monthly oral option. Zoledronic acid (Reclast), approved in 2007, offered a once-yearly intravenous infusion, addressing the strict fasting and positioning requirements that made oral bisphosphonates difficult for women with reflux, dysphagia, or adherence challenges. The HORIZON Key Fracture Trial showed zoledronic acid reduced vertebral fracture risk by 70% and hip fracture risk by 41% over 3 years.

The Atypical Femur Fracture and ONJ Signals

Long-term bisphosphonate use brought two rare but real safety concerns: atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ). The FDA added an AFF warning in 2010. The absolute risk remains low, estimated at 3.2-50 per 100,000 person-years depending on duration, but the signal is real enough that current guidelines recommend reassessing after 3-5 years and considering a drug holiday for lower-risk women.

SERMs: A Middle Path for Women Who Cannot Take Hormones

Selective estrogen receptor modulators (SERMs) offered an option for women who wanted bone protection without systemic estrogen effects. Raloxifene (Evista), approved for osteoporosis in 1997, acts as an estrogen agonist in bone and an antagonist in breast and uterine tissue.

The MORE (Multiple Outcomes of Raloxifene Evaluation) trial enrolled 7,705 postmenopausal women and showed raloxifene reduced vertebral fracture risk by 30-50% depending on baseline fracture status, though it did not significantly reduce hip fracture risk. A secondary finding, later investigated in the STAR trial, was a significant reduction in invasive breast cancer risk, making raloxifene particularly relevant for women at elevated breast cancer risk who also need bone protection.

Raloxifene increases the risk of venous thromboembolism, similar in magnitude to estrogen, which limits its use in women with clotting history. It also worsens hot flashes, making it poorly tolerated in early postmenopause when vasomotor symptoms are already a burden.

Denosumab: Targeting RANKL Directly

Denosumab (Prolia) brought a fundamentally new mechanism when the FDA approved it in 2010. A monoclonal antibody against RANK ligand, it mimics the action of osteoprotegerin, directly blocking osteoclast formation and activity. Given as a subcutaneous injection every 6 months, it represented the first biologic therapy for osteoporosis.

The FREEDOM trial enrolled 7,808 postmenopausal women and showed denosumab reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 3 years. These effect sizes exceeded most bisphosphonate data in direct comparison, though the trials were not head-to-head.

The Rebound Problem Women Need to Know About

Denosumab has a critical discontinuation risk that distinguishes it from bisphosphonates. Because it has no residual skeletal binding, stopping denosumab abruptly causes rapid bone resorption rebound, and multiple vertebral fractures have been reported within 12-18 months of discontinuation. Current NAMS and Endocrine Society guidance is clear: if you stop denosumab, you must transition to a bisphosphonate to consolidate its gains. This is a conversation every woman starting Prolia needs to have with her prescriber before the first injection.

Anabolic Therapies: Building New Bone Instead of Just Preserving It

All therapies discussed so far are anti-resorptive. They slow bone loss but do not meaningfully increase bone formation. Anabolic agents work differently. They stimulate osteoblast activity and generate genuinely new bone.

Teriparatide: The First Bone Builder

Teriparatide (Forteo), a recombinant fragment of parathyroid hormone (PTH 1-34), received FDA approval in 2002 for postmenopausal women at high fracture risk. The key fracture prevention trial enrolled 1,637 postmenopausal women and showed a 65% reduction in new vertebral fractures and a 53% reduction in nonvertebral fragility fractures over a median of 21 months.

Teriparatide is given as a daily subcutaneous injection for a maximum of 24 months total lifetime use. After stopping, an anti-resorptive agent is required to preserve the bone built during treatment. The drug carried a black-box warning for osteosarcoma based on rat studies at supraphysiologic doses. Long-term pharmacovigilance data have not confirmed an osteosarcoma signal in humans, and the FDA removed the black-box warning in 2020.

Abaloparatide: A PTHrP Analog

Abaloparatide (Tymlos), a parathyroid hormone-related protein (PTHrP) analog, was approved in 2017. The ACTIVE trial of 2,463 postmenopausal women showed a 43% reduction in major osteoporotic fractures versus placebo. Abaloparatide also showed a slightly lower rate of hypercalcemia than teriparatide, which may make it more tolerable for some women.

Romosozumab: The Dual-Action Newcomer

Romosozumab (Evenity), approved by the FDA in April 2019, works by blocking sclerostin, a protein that inhibits bone formation. Blocking sclerostin simultaneously increases bone formation and decreases bone resorption, a dual mechanism no prior drug achieved.

The FRAME trial, enrolling 7,180 postmenopausal women, showed romosozumab reduced new vertebral fractures by 73% compared to placebo over 12 months. The ARCH trial compared romosozumab followed by alendronate against alendronate alone, and the sequential romosozumab-then-alendronate strategy reduced hip fracture risk by 38% more than alendronate alone. Romosozumab carries a black-box warning for cardiovascular events after the ARCH trial found a small excess of serious cardiac events in women with pre-existing cardiovascular disease; it is contraindicated in women who have had a myocardial infarction or stroke in the past year.

Romosozumab is given as two subcutaneous injections monthly for exactly 12 months, then transitioned to an anti-resorptive. This fixed-duration framing is a practical advance: it creates a defined treatment arc that women can plan around.

How Guidelines Have Evolved With the Evidence

NAMS and the Menopause Society

The North American Menopause Society (NAMS, now The Menopause Society) has published osteoporosis position statements approximately every 4-5 years since the 1990s. The 2021 NAMS position statement on nonhormonal management of menopause and related bone health guidance now incorporate FRAX-based fracture risk thresholds, sequential therapy concepts, and the monitoring of drug holidays, none of which existed in the 1990s guidelines.

ACOG and Perimenopause-Specific Guidance

ACOG Practice Bulletin 129 (with subsequent updates) recommends screening with DXA at age 65, or earlier for women under 65 with risk factors including early menopause (before age 45), low body weight (BMI <20), smoking, or a parental history of hip fracture. ACOG explicitly acknowledges that perimenopausal women with risk factors may warrant earlier bone density monitoring.

The FRAX Tool: Putting Risk Into Numbers

The WHO's FRAX algorithm, launched in 2008, calculates a 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors with or without bone mineral density. Current National Osteoporosis Foundation (NOF) guidance recommends treatment when the 10-year probability of hip fracture exceeds 3% or major osteoporotic fracture exceeds 20%. FRAX scores are sex-specific; women have separate reference populations from men, reflecting the biological difference in fracture epidemiology.

Pregnancy, Lactation, and Bone: What Every Woman Should Know

Osteoporosis medications present serious considerations across the reproductive years, and this is one area where female-specific data gaps are real and clinically meaningful.

Bisphosphonates and Pregnancy

Bisphosphonates are classified as FDA Pregnancy Category D (old system) or carry explicit contraindication language under the current labeling framework. They incorporate into the maternal skeleton for years to decades after a course of treatment, and animal studies show fetal skeletal toxicity. Case series of women who became pregnant after bisphosphonate exposure have not identified a consistent pattern of birth defects, but the human data are limited. Current guidance from ACOG and The Menopause Society is that bisphosphonates should be used with caution in women who may still conceive, and that women of reproductive age taking bisphosphonates should use reliable contraception.

Teriparatide, abaloparatide, denosumab, and romosozumab are all contraindicated in pregnancy based on animal data and absence of human safety data. Raloxifene is also contraindicated in pregnancy.

Pregnancy-Associated Osteoporosis

A separate condition, pregnancy-associated osteoporosis, typically manifests as vertebral fractures in the third trimester or immediately postpartum, often in otherwise healthy women with no prior bone diagnosis. Its estimated incidence is 0.4 per 100,000 deliveries, but under-recognition is likely. Most cases resolve partially with calcium, vitamin D, and breastfeeding cessation, though some require pharmacologic treatment postpartum. This is distinct from postmenopausal osteoporosis but shares some underlying biology.

Lactation-Related Bone Loss

Women lose 3-5% of bone mass during lactation, primarily from parathyroid hormone-related protein (PTHrP)-driven resorption independent of calcium intake. This loss is largely reversible after weaning, but women with multiple closely spaced pregnancies and prolonged lactation should be aware of the cumulative impact, particularly if they have other risk factors.

Who This Treatment History Is Most Relevant For, by Life Stage

Reproductive years (20s-30s): Bone accrual is the goal, not treatment. Peak bone mass is reached by approximately age 30. Adequate calcium (1,000 mg/day), vitamin D (600-800 IU/day), and weight-bearing exercise are the tools. Women with amenorrhea from eating disorders, athletic over-training, or premature ovarian insufficiency (POI) need evaluation earlier.

Perimenopause (typically 40s-early 50s): Bone loss starts here. DXA baseline may be warranted if risk factors are present. Hormone therapy, if started in this window for menopausal symptom management, also provides bone protection. This is the period most under-served by the historical treatment literature, which focused almost exclusively on postmenopausal women.

Early postmenopause (within 10 years of final menstrual period): The highest-velocity bone loss phase. Anti-resorptive therapy (bisphosphonate or denosumab) is the current first-line pharmacologic choice for women with T-score at or below -2.5 or a FRAX score meeting treatment thresholds. Hormone therapy remains a reasonable option for women who also have vasomotor symptoms, per The Menopause Society 2022 position statement.

Late postmenopause (more than 10 years after final menstrual period, or age 60+): The cardiovascular risk picture for HT changes, and bisphosphonates or denosumab are typically preferred for bone. High-risk women (T-score below -2.5 with prior fracture, or T-score below -3.0) should be considered for anabolic-first therapy (romosozumab or teriparatide) followed by anti-resorptive consolidation.

Women with PCOS: PCOS-related hyperandrogenism may partially offset estrogen-deficiency bone loss in reproductive years, but this protection is not guaranteed and dissipates at menopause. Women with PCOS who used depot medroxyprogesterone acetate (DMPA) for contraception may have additional bone density concerns to discuss with their clinician.

The Evidence Gap Women Deserve to Know About

Women have been enrolled in osteoporosis fracture trials at much higher rates than in most other disease areas, which is a genuine strength of the osteoporosis evidence base. The FIT, FREEDOM, FRAME, and HORIZON trials all enrolled exclusively or predominantly postmenopausal women.

The gaps, however, are real in specific subpopulations. Women of color, particularly Black and Hispanic women, have been consistently under-represented in major fracture trials despite having different baseline bone density distributions and fracture patterns. FRAX was calibrated primarily in white European populations, and its performance in Black American women has been questioned because FRAX may systematically underestimate fracture risk in this group. Perimenopausal women, women with POI, and women under 50 with fragility fractures also lack strong randomized trial data specific to their situations.

What Sequential Therapy Looks Like Today

Modern osteoporosis management for high-risk postmenopausal women is increasingly sequential rather than a single drug chosen and continued indefinitely. The current Endocrine Society 2019 guideline on pharmacological management of osteoporosis in postmenopausal women recommends anabolic therapy first for women at very high fracture risk, followed by anti-resorptive consolidation, a sequence backed by the ARCH and ACTIVExtend trial data.

A simplified evidence-based framework:

• Very high fracture risk (T-score below -2.5 with prior major fracture): start romosozumab 12 months, then transition to alendronate or zoledronic acid.
• High fracture risk without prior fracture: bisphosphonate (alendronate, risedronate, or zoledronic acid) or denosumab as first line.
• Women also needing vasomotor symptom relief: hormone therapy addresses both needs in the early postmenopausal window.
• Drug holiday after bisphosphonate: consider after 3-5 years of oral bisphosphonate or 3 years of zoledronic acid in women whose T-score has reached above -2.5 and who have no prior hip or vertebral fracture.

The 6-month subcutaneous injection schedule of denosumab offers a concrete adherence advantage over weekly or monthly oral bisphosphonates. Missed doses of denosumab, however, carry rebound risk, making injection tracking essential.